Alessandro Bittoni

8PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersMedical biochemistry - proteins and peptides (incl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 22, 2026
On-Treatment Grade 3-4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence.

|Oct 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Carlo Signorelli, Michele Basso, Maria Alessandra Calegari

|Jun 26, 2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone

|Dec 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone

|Oct 26, 2024
Multigene Panel Next-Generation Sequencing Techniques in the Management of Patients with Metastatic Colorectal Carcinoma: The Way Forward for Personalized Treatment? A Single-Center Experience.

Laura Matteucci, Francesco Giulio Sullo, Chiara Gallio

|May 11, 2024
Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer.

Francesco Giulio Sullo, Alessandro Passardi, Chiara Gallio

Pageof 2

Frequent Collaborators

7 joint publications

Alessandro Passardi

4 joint publications

Giulia Arrivi

4 joint publications

Ina Valeria Zurlo

4 joint publications

Fiorenza Santamaria